ENORAMA PHARMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.54 SEK | -5.58% |
|
-27.43% | -18.06% |
| 02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
| 02-21 | Enorama Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 12.8M 1.19M 1.63M | Sales 2022 | 6.85M 638K 873K | Capitalization | 28.05M 2.61M 3.58M |
|---|---|---|---|---|---|
| Net income 2021 | -27M -2.52M -3.44M | Net income 2022 | -42M -3.91M -5.36M | EV / Sales 2021 | 12.7 x |
| Net cash position 2021 | 8.41M 784K 1.07M | Net cash position 2022 | 2.23M 208K 284K | EV / Sales 2022 | 3.77 x |
| P/E ratio 2021 |
-4.97
x | P/E ratio 2022 |
-0.68
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.4% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.58% | ||
| 1 week | -27.43% | ||
| Current month | -9.29% | ||
| 1 month | +10.43% | ||
| 3 months | -66.04% | ||
| 6 months | -14.19% | ||
| Current year | -18.06% |
1 week
2.20
2.94
1 month
2.203.50
Current year
2.0010.50
1 year
2.0010.50
3 years
2.0043.85
5 years
2.00110.00
10 years
2.00177.00
| Managers | Title | Age | Since |
|---|---|---|---|
Annette Agerskov
CEO | Chief Executive Officer | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 15-12-31 | |
| - | - | ||
Daniel Schroeder
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 2.54 | -5.58% | 15,192 |
| 24-05-21 | 2.69 | -0.74% | 350,785 |
| 24-05-20 | 2.71 | -5.24% | 32,921 |
| 24-05-17 | 2.86 | +4.00% | 72,963 |
| 24-05-16 | 2.75 | -21.43% | 133,372 |
Delayed Quote Nasdaq Stockholm, May 22, 2024 at 11:13 am
More quotes
Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.06% | 9.69M | |
| +17.79% | 22.02B | |
| +18.55% | 15.08B | |
| +20.58% | 14.37B | |
| +57.43% | 13.06B | |
| -9.70% | 6.75B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.66% | 5.64B | |
| +4.00% | 4.66B |
- Stock Market
- Equities
- ERMA Stock
